Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report) fell 6.8% on Tuesday after Citigroup lowered their price target on the stock from $43.00 to $42.00. Citigroup currently has a buy rating on the stock. Summit Therapeutics traded as low as $10.82 and last traded at $11.0190. Approximately 2,758,735 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 4,719,630 shares. The stock had previously closed at $11.82.
Several other equities research analysts have also recently commented on SMMT. Sanford C. Bernstein reiterated a "market perform" rating on shares of Summit Therapeutics in a research report on Monday, October 5th. Wall Street Zen raised shares of Summit Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, September 5th. Summit Redstone set a $25.00 price objective on Summit Therapeutics in a report on Wednesday, September 9th. Cantor Fitzgerald restated an "overweight" rating on shares of Summit Therapeutics in a report on Tuesday, September 22nd. Finally, Guggenheim reiterated a "buy" rating on shares of Summit Therapeutics in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $28.38.
Read Our Latest Stock Analysis on Summit Therapeutics
Key Summit Therapeutics News
Investors following SMMT have been watching these news items:
- Neutral Sentiment: Barclays lowered its target to $18 and kept an Equal Weight rating. The divergent analyst outlooks offer limited reassurance against the regulatory setback. Barclays rating
- Negative Sentiment: The FDA issued a Complete Response Letter (CRL) for ivonescimab, citing insufficient overall-survival evidence despite positive progression-free-survival results. The drug is not approved, and the decision raises uncertainty about what additional evidence or clinical work may be needed before a resubmission. Reuters report on FDA decision
- Negative Sentiment: The FDA decision drove SMMT to a new 52-week low after several sessions of declines, reflecting investors’ reassessment of the drug’s approval prospects and near-term commercial potential. Report on Summit’s 52-week low
Hedge Funds Weigh In On Summit Therapeutics
Hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Summit Therapeutics in the second quarter valued at approximately $138,838,000. Bellevue Group AG raised its holdings in shares of Summit Therapeutics by 13,733.9% in the third quarter. Bellevue Group AG now owns 2,113,681 shares of the company's stock valued at $35,742,000 after purchasing an additional 2,098,402 shares during the last quarter. Candriam S.C.A. lifted its position in shares of Summit Therapeutics by 212.3% during the 3rd quarter. Candriam S.C.A. now owns 1,662,969 shares of the company's stock worth $28,224,000 after buying an additional 1,130,537 shares in the last quarter. Bank of America Corp DE bought a new stake in Summit Therapeutics during the second quarter worth $12,603,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Summit Therapeutics by 34.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 592,810 shares of the company's stock worth $11,240,000 after purchasing an additional 151,857 shares during the period. Institutional investors own 4.61% of the company's stock.
Summit Therapeutics Price Performance
The stock's 50 day simple moving average is $16.30 and its two-hundred day simple moving average is $16.12. The stock has a market capitalization of $8.81 billion, a PE ratio of -10.34 and a beta of -1.49.
About Summit Therapeutics
(
Get Free Report)
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit's licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Summit Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.
While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.